Flu medicine banned in the US! Flu medicine banned in the US!

BioNTech announced on Monday that it will likely lose 900 million euros in the third quarter of this year from the Covid-19 vaccines it produces with its partner Pfizer.

BioNTech's partner Pfizer announced on Friday that its Covid-19 vaccine and treatment will be downsized by $3.5 billion due to lower than expected sales, while cutting its annual revenue forecast by 13 percent.

Pfizer said it would take a non-cash charge of $5.5 billion in the third quarter to write off $4.6 billion of Paxlovid and $900 million of inventory write-offs and other charges for the vaccine.

In a statement made by BioNTech today, it was noted that the loss related to stock write-offs and other charges for Comirnaty, the Covid-19 vaccine co-produced with Pfizer, could reach 900 million euros in the third quarter.

BioNTech reported that this loss, which will be recorded on the balance sheet in the third quarter, will also reduce 2023 revenues.

Vaccine sales fall, companies' income also decreased
According to Reuters, a BioNTech spokesperson declined to comment on comments that the company expects revenues of 5 billion euros in 2023 inventory.

The German company will announce final figures for the third quarter on November 6.